Richard Kaplan

Richard Kaplan

Auto-generated profile, based on publicly available information

Richard Kaplan

Desmond Tutu HIV Foundation

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Lancet
Verified
Journal Article
Closed access
PCPedro Cahn
Pedro Cahn
JMJuan Sierra Madero
Juan Sierra Madero
JAJosé Ramón Arribas
José Ramón Arribas
AAAndrea Antinori
Andrea Antinori
RORoberto Ortiz
Roberto Ortiz
AUAndrew Ustianowski
Andrew Ustianowski

30 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAnkur Gupta
Ankur Gupta
RWRobin Wood
Robin Wood
RKRichard Kaplan
Richard Kaplan
LBLinda-Gail Bekker
Linda-Gail Bekker
SLStephen D Lawn
Stephen D Lawn
Although antiretroviral therapy (ART) is known to be associated with time-dependent reductions in tuberculosis (TB) incidence, the long-term impact of ART on incidence remains imprecisely defined due to limited duration of follow-up and incomplete CD4 cell count recovery in existing studies. We determined TB incidence in a South African ART cohort with up to 8 years of follow-up and stratified rates according to CD4 cell count recovery. We compared these rates with those of HIV-uninfected individuals living in the same community. Prospectively collected clinical data on patients receiving ART in a community-based cohort in Cape Town were analysed. 1544 patients with a median follow-up of 5.0 years (IQR 2.4–5.8) were included in the analysis. 484 episodes of incident TB (73.6% culture-confirmed) were diagnosed in 424 patients during 6506 person-years (PYs) of follow-up. The TB incidence rate during the first year of ART was 12.4 (95% CI 10.8–14.4) cases/100PYs and decreased to 4.92 (95% CI 3.64–8.62) cases/100PYs between 5 and 8 years of ART. During person-time accrued within CD4 cell strata 0–100, 101–200, 201–300, 301–400, 401–500, 501–700 and ≥700 cells/µL, TB incidence rates (95% CI) were 25.5 (21.6–30.3), 11.2 (9.4–13.5), 7.9 (6.4–9.7), 5.0 (3.9–6.6), 5.1 (3.8–6.8), 4.1 (3.1–5.4) and 2.7 (1.7–4.5) cases/100PYs, respectively. Overall, 75% (95% CI 70.9–78.8) of TB episodes were recurrent cases. Updated CD4 cell count and viral load measurements were independently associated with long-term TB risk. TB rates during person-time accrued in the highest CD4 cell count stratum (>700 cells/µL) were 4.4-fold higher that the rate in HIV uninfected individuals living in the same community (2.7 versus 0.62 cases/100PYs; 95%CI 0.58–0.65). TB rates during long-term ART remained substantially greater than rates in the local HIV uninfected populations regardless of duration of ART or attainment of CD4 cell counts exceeding 700 cells/µL.

1 March 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
MAMichael Aboud
Michael Aboud
RKRichard Kaplan
Richard Kaplan
JLJohannes Lombaard
Johannes Lombaard
FZFujie Zhang
Fujie Zhang
JHJosé A Hidalgo
José A Hidalgo
KSKimberly Smith
Kimberly Smith

31 August 2018 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
COChloe Orkin
Chloe Orkin
KSKathleen E Squires
Kathleen E Squires
JMJean-Michel Molina
Jean-Michel Molina
PSPaul E Sax
Paul E Sax
WWWing-Wai Wong
Wing-Wai Wong
DGDRIVE-AHEAD Study Group
DRIVE-AHEAD Study Group
Doravirine (DOR), a novel non-nucleoside reverse-transcriptase inhibitor (NNRTI), is active against wild-type Human Immunodeficiency Virus (HIV)-1 and the most common NNRTI-resistant variants, and has a favorable and unique in vitro resistance profile. DRIVE-AHEAD is a phase 3, double-blind, non-inferiority trial. Antiretroviral treatment–naive adults with ≥1000 HIV-1 RNA copies/mL were randomized (1:1) to once-daily, fixed-dose DOR at 100 mg, lamivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz at 600 mg, emtricitabine at 200 mg, and TDF at 300 mg (EFV/FTC/TDF) for 96 weeks. The primary efficacy endpoint was the proportion of participants with <50 HIV-1 RNA copies/mL at week 48 (Food and Drug Administration snapshot approach; non-inferiority margin 10%). Of the 734 participants randomized, 728 were treated (364 per group) and included in the analyses. At week 48, 84.3% (307/364) of DOR/3TC/TDF recipients and 80.8% (294/364) of EFV/FTC/TDF recipients achieved <50 HIV-1 RNA copies/mL (difference 3.5%, 95% CI, -2.0, 9.0). DOR/3TC/TDF recipients had significantly lower rates of dizziness (8.8% vs 37.1%), sleep disorders/disturbances (12.1% vs 25.2%), and altered sensorium (4.4% vs 8.2%) than EFV/FTC/TDF recipients. Mean changes in fasting low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were significantly different between DOR/3TC/TDF and EFV/FTC/TDF (−1.6 vs +8.7 mg/dL and −3.8 vs +13.3 mg/dL, respectively). In HIV-1 treatment-naive adults, DOR/3TC/TDF demonstrated non-inferior efficacy to EFV/FTC/TDF at week 48 and was well tolerated, with significantly fewer neuropsychiatric events and minimal changes in LDL-C and non–HDL-C compared with EFV/FTC/TDF. NCT02403674

1 January 2011 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MNMweete D Nglazi
Mweete D Nglazi
SLStephen D Lawn
Stephen D Lawn
RKRichard Kaplan
Richard Kaplan
KKKatharina Kranzer
Katharina Kranzer
COCatherine Orrell
Catherine Orrell
LBLinda-Gail Bekker
Linda-Gail Bekker
Objectives: To assess sustainability of programmatic outcomes in a community-based antiretroviral therapy (ART) service in South Africa during 7 years of scale-up. Methods: Prospective cohort of treatment-naive patients aged ≥15 years enrolled between 2002 and 2008. Data were analyzed by calendar period of ART initiation using time-to-event analysis and logistic regression. Results: ART was initiated by 3162 patients (67% women; median age, 34 years) who were followed-up for a median of 2.4 years (interquartile range, 1.2-3.8). After 6 years, the cumulative probability of death and loss to follow-up (LTFU) was 37.4%. The probabilities of transfer-out to another ART service and of virological failure were 21.6% and 23.1%, respectively. Low mortality risk and excellent virological and immunological responses during the first year of ART were not associated with calendar period of ART initiation. In contrast, risk of LTFU and virological failure both increased between successive calendar periods in unadjusted and adjusted analyses. The number of patients per member of clinic staff increased markedly over time. Conclusions: Successful early outcomes (low mortality and good immunological and virological responses) were sustained between sequential calendar periods during 7 years of scale-up. In contrast, the increasing cumulative probabilities of LTFU or virological failure may reflect decreasing capacity to adequately support patients during long-term therapy as clinic caseload escalated.

8 July 2009 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
MCMorna Cornell
Morna Cornell
LMLandon Myer
Landon Myer
RKRichard Kaplan
Richard Kaplan
LBLinda‐Gail Bekker
Linda‐Gail Bekker
RWRobin Wood
Robin Wood
Summary: Objectives  Despite the rapid expansion of antiretroviral therapy (ART) services in Africa, there are few data on whether outcomes differ for women and men and what factors may drive such variation. We investigated the association of gender and income with survival and retention in a South African ART programme.Methods  A total of 2196 treatment‐naïve adults were followed for 1 year on ART. Proportional hazards regression was used to explore associations between baseline characteristics and survival and loss‐to‐follow‐up (LTFU).Results  Patients were predominantly female (67%). Men presented at an older age and with more advanced HIV disease, and during early ART the crude death rate was higher among men than women (22.8 vs 12.5/100 person‐years; P = 0.002). However in multivariate analysis, gender was not significantly associated with survival after adjusting for baseline clinical and immunovirological status (HR = 1.46, 95% CI = 0.96–2.22; P = 0.076). In late ART (4–12 months), there was no gender difference in mortality rates (3.5 vs 3.8/100 person‐years; P = 0.817). In multivariate analysis, survival was strongly associated with age (HR = 1.05, 95% CI = 1.02–1.09; P < 0.001), CD4 count >150 vs <50 cells/μl (HR = 0.35, 95% CI = 0.14–0.87; P = 0.023) and any monthly income vs none (HR = 0.47, 95% CI = 0.25–0.88; P = 0.018). Having some monthly income was protective against LTFU at 1 year on ART (adjusted HR = 0.56, 95% CI = 0.39–0.82; P = 0.002).Conclusion  Men’s high early mortality on ART appears due largely to their presentation with more advanced HIV disease. Efforts are needed to enrol men into care earlier in HIV disease and to reduce socio‐economic inequalities in ART programme outcomes.